Blue Arrow Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Blue Arrow Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-33,000	Closed	-$4.11M	–	148
2015 Q1	$4.11M	Buy	33,000 +10,041	+44%	+$1.06M	0.4%	71
2014 Q4	$2.08M	Buy	+22,959	New	+$1.91M	0.23%	103
2014 Q3	–	Sell	-4,600	Closed	-$286K	–	187
2014 Q2	$286K	Buy	+4,600	New	+$278K	0.04%	125

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Blue Arrow Capital Management's BMRN Position: Q2 2015 in Review

Blue Arrow Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2015, closing a stake of 33,000 shares — an estimated $4.11M sold.

Blue Arrow Capital Management first reported a position in BMRN in Q2 2014 and held it in 3 quarters. The position peaked at $4.11M in Q1 2015. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

Blue Arrow Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Blue Arrow Capital Management sold 33,000 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $4.11M.
Blue Arrow Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 3 quarters.
Blue Arrow Capital Management's BioMarin Pharmaceuticals position peaked at $4.11M in Q1 2015.
392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on Blue Arrow Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.